WO2022220598A1 - Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate - Google Patents

Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate Download PDF

Info

Publication number
WO2022220598A1
WO2022220598A1 PCT/KR2022/005375 KR2022005375W WO2022220598A1 WO 2022220598 A1 WO2022220598 A1 WO 2022220598A1 KR 2022005375 W KR2022005375 W KR 2022005375W WO 2022220598 A1 WO2022220598 A1 WO 2022220598A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
chloro
crystalline form
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/KR2022/005375
Other languages
English (en)
Korean (ko)
Inventor
김지윤
전슬아
박기숙
김성원
Original Assignee
주식회사 엘지화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지화학 filed Critical 주식회사 엘지화학
Priority to CN202280026332.XA priority Critical patent/CN117120425A/zh
Publication of WO2022220598A1 publication Critical patent/WO2022220598A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a crystalline form of a sphingosine-1-phosphate receptor agonist, and more particularly, 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazole- 5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof;
  • Sphingosine-1-phosphate is produced through the intracellular ceramide pathway, and ceramide, the starting material of this synthetic pathway, has two production pathways, namely, the de novo biosynthetic pathway and It is produced in cells through the degradation of sphingomyelin, a component of the cell membrane.
  • S1P levels in each tissue are regulated by two biosynthetic sphingosine kinases (SphKs) and two biodegradable S1P phosphatases (S1P lyase and lysophospholipid phosphatases).
  • S1P lyase and lysophospholipid phosphatases The produced substance S1P mediates various cellular responses such as cell proliferation, cytoskeletal organization and migration, adhesion- and tight junction assembly, and morphogenesis. it is known They are present in high concentrations (100-1000 nM) in plasma bound to albumin and other plasma proteins, whereas in tissues, they are present in low concentrations.
  • S1P binds to the S1P receptor, a G-protein coupled receptor, and exhibits various biological functions.
  • the sub-types of S1P receptors known to date are S1P1 to S1P5. ) receptor) 1, 5, 3, 6 and 8. These S1P receptors are responsible for leukocyte recirculation, neural cell proliferation, morphological changes, migration, endothelial function, vasoregulation and cardiovascular development ( It is known to be involved in various biological functions such as cardiovascular development.
  • crystal form with a different structure can be obtained depending on the recrystallization conditions during the drug manufacturing process, i.e., recrystallization solvent, drug concentration, heating and cooling rate, temperature, stirring rate, etc.
  • recrystallization solvent i.e., recrystallization solvent, drug concentration, heating and cooling rate, temperature, stirring rate, etc.
  • special attention must be paid to the control of the manufacturing process.
  • the difference in crystal structure is distinguished as an X-ray diffraction diagram. Chemical properties showing pharmacological effects do not change, only physical properties such as crystallinity, hygroscopicity, melting point, solubility, and dissolution rate change, so it has a very important meaning in terms of pharmaceuticals, like polymorphism (Morris, K. R. et al. , Int. J. Pharm., 108, 1994, 15-206).
  • the present invention is 1- [1-chloro-6- (3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy) -3,4-dihydro-naphthalen-2-ylmethyl of the formula 1 It is intended to provide a crystalline form having pharmaceutically excellent properties of ]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof:
  • the present invention is 1- [1-chloro-6- (3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy) -3,4-dihydro-naphthalene-2- provided is a crystalline form of ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof.
  • the present invention as an active ingredient 1- [1-chloro-6- (3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy) -3,4-dihydro-naphthalene-2-
  • a pharmaceutical composition comprising a crystalline form of ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier.
  • -6-(3-Chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid, or Crystalline forms of pharmaceutically acceptable salts or solvates thereof are provided: 8.72 ⁇ 0.2°, 9.14 ⁇ 0.2°, 12.75 ⁇ 0.2°, 13.85 ⁇ 0.2°, 15.59 ⁇ 0.2°, 16.09 ⁇ 0.2°, 17.74 ⁇ 0.2° , 18.4 ⁇ 0.2°, 19.23 ⁇ 0.2°, 20.17 ⁇ 0.2°, 20.82 ⁇ 0.2°, 22.88 ⁇ 0.2°, 23.51 ⁇ 0.2°, 24.71 ⁇ 0.2°, 25.13 ⁇ 0.2°, 26.87 ⁇ 0.2°, 28.13 ⁇ 0.2° and 31.51 ⁇ 0.2°
  • the crystalline Form C has 3 or more, 5 or more, 7 or more, 9 or more or 10 or more characteristic peaks (2 ⁇ ) selected from the following X-ray diffraction pattern spectra: 8.72 ⁇ 0.1°, 9.14 ⁇ 0.1°, 12.75 ⁇ 0.1°, 13.85 ⁇ 0.1°, 15.59 ⁇ 0.1°, 16.09 ⁇ 0.1°, 17.74 ⁇ 0.1°, 18.4 ⁇ 0.1°, 19.23 ⁇ 0.1°, 20.17 ⁇ 0.1°, 20.82 ⁇ 0.1°, 22.88 ⁇ 0.1°, 23.51 ⁇ 0.1°, 24.71 ⁇ 0.1°, 25.13 ⁇ 0.1°, 26.87 ⁇ 0.1°, 28.13 ⁇ 0.1° and 31.51 ⁇ 0.1°.
  • thermogravimetric analysis TGA
  • a weight loss of about 17.0% is observed at 26 to 115°C and a weight loss of 7.1% is observed at 115 to 140°C (FIG. 2).
  • DSC differential scanning calorimetry
  • the crystalline form is referred to the crystalline form.
  • the crystalline form F has 3 or more, 5 or more, 7 or more, 9 or more or 10 or more characteristic peaks (2 ⁇ ) selected from the following X-ray diffraction pattern spectra: 7.68 ⁇ 0.1°, 9.92 ⁇ 0.1°, 14.26 ⁇ 0.1°, 14.78 ⁇ 0.1°, 15.78 ⁇ 0.1°, 16.38 ⁇ 0.1°, 18.72 ⁇ 0.1°, 21.34 ⁇ 0.1°, 21.74 ⁇ 0.1°, 22.38 ⁇ 0.1°, 22.84 ⁇ 0.1°, 24.42 ⁇ 0.1°, 25 ⁇ 0.1°, 27.7 ⁇ 0.1°, 28.64 ⁇ 0.1° and 29.9 ⁇ 0.1°.
  • thermogravimetric analysis TGA
  • weight loss of about 8.4% and 5.6% is observed at about 39 to 125°C and 200 to 255°C, respectively (FIG. 5).
  • DSC differential scanning calorimetry
  • the crystalline form II has 3 or more, 5 or more, 7 or more, 9 or more, or 10 or more characteristic peaks (2 ⁇ ) selected from the following X-ray diffraction pattern spectra: 13.97 ⁇ 0.1o, 15.40 ⁇ 0.1o, 15.81 ⁇ 0.1o, 19.38 ⁇ 0.1o, 19.81 ⁇ 0.1o, 21.18 ⁇ 0.1o, 21.86 ⁇ 0.1o, 23.55 ⁇ 0.1o, 24.81 ⁇ 0.1o, 25.08 ⁇ 0.1o, 25.49 ⁇ 0.1o, 26.00 ⁇ 0.1o, 27.40 ⁇ 0.1o, 28.01 ⁇ 0.1o, 30.96 ⁇ 0.1o, 31.87 ⁇ 0.1o, 32.53 ⁇ 0.1o and 35.09 ⁇ 0.1o.
  • thermogravimetric analysis TGA
  • a weight loss of about 3.0% is observed at 30 to 65° C.
  • a weight loss of about 3.3% is observed at 65 to 95° C.
  • a weight loss of about 0.4% is observed.
  • DSC differential scanning calorimetry
  • a broad endothermic peak was observed at 65 to 115° C. corresponding to the weight loss of TGA.
  • a small endotherm is observed at about 128°C (onset), and an endothermic peak at 170 to 190°C corresponding to the weight loss of TGA is observed.
  • the crystalline form is
  • the crystalline form V has 3 or more, 5 or more, 7 or more, 9 or more or 10 or more characteristic peaks (2 ⁇ ) selected from the following X-ray diffraction pattern spectra: 7.25 ⁇ 0.1o, 13.36 ⁇ 0.1o, 14.32 ⁇ 0.1o, 16.43 ⁇ 0.1o, 17.94 ⁇ 0.1o, 18.22 ⁇ 0.1o, 19.85 ⁇ 0.1o, 20.65 ⁇ 0.1o, 21.74 ⁇ 0.1o, 22.23 ⁇ 0.1o, 23.46 ⁇ 0.1o, 24.78 ⁇ 0.1o, 25.88 ⁇ 0.1o, 26.34 ⁇ 0.1o, 26.84 ⁇ 0.1o and 31.58 ⁇ 0.1o.
  • thermogravimetric analysis TGA
  • a weight loss of about 13.3% is observed at about 85 to 140°C
  • a weight loss of about 0.9% is observed at about 210 to 225°C.
  • DSC differential scanning calorimetry
  • the pharmaceutically acceptable salt is hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and naphthalenesulfonic acid.
  • the pharmaceutically acceptable salt may be hydrochloric acid.
  • 1- [1-chloro-6- (3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy) -3,4-dihydro-naphthalene- in the crystallization solvent preparing a mixed solution by dissolving 2-ylmethyl]-piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof;
  • a method for preparing the crystalline Form C, the crystalline Form F, the crystalline Form II and/or the crystalline Form V comprising: obtaining a crystal from the mixed solution.
  • the crystallization solvent may be selected from water, a polar aprotic organic solvent, and a mixture thereof, but is not limited thereto.
  • the organic solvent may be selected from dimethylformamide, acetonitrile, dioxane, dimethyl sulfoxide, tetrahydrofuran, xylene, and mixtures thereof, but is not limited thereto.
  • the 1- [1-chloro-6- (3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy) -3,4-dihydro-naphthalene-2- comprising Form C, Form F, Form II and/or Form V of ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier
  • a pharmaceutical composition is provided.
  • pharmaceutical composition may include other chemical ingredients such as carriers, diluents, excipients and the like in addition to the active compound according to the present invention. Accordingly, the pharmaceutical composition may include a pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof, if necessary.
  • the pharmaceutical composition facilitates administration of the active compound into an organism.
  • Various techniques for administering a compound exist, including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
  • carrier refers to a compound that facilitates the introduction of the compound into a cell or tissue.
  • DMSO dimethylsulfoxide
  • carrier facilitates the introduction of many organic compounds into cells or tissues of living organisms.
  • diluent is defined as a compound that is diluted in water to dissolve the compound as well as to stabilize the biologically active form of the compound. Salts dissolved in buffers are used as diluents in the art. A commonly used buffer is phosphate buffered saline, which mimics the salt form of human solutions. Because buffer salts can control the pH of a solution at low concentrations, it is rare for a buffered diluent to modify the biological activity of a compound.
  • pharmaceutically acceptable refers to a property that does not impair the biological activity and physical properties of a compound.
  • the crystalline form of the compound of Formula 1 may be formulated into various pharmaceutical dosage forms as desired.
  • the pharmaceutical composition according to the present invention to prepare the active ingredient, specifically, the crystalline form C, the crystalline form F, the crystalline form II and / or the crystalline form V of the compound of Formula 1 or a pharmaceutically acceptable salt or solvate thereof It is mixed with various pharmaceutically acceptable carriers that can be selected according to the formulation to be used.
  • the pharmaceutical composition according to the present invention may be formulated as an injectable preparation, an oral preparation, etc. as desired.
  • the crystalline form of the compound of formula (1) of the present invention may be formulated by a known method using a known pharmaceutical carrier and excipient, and then put into a unit dose form or a multi-dose container.
  • the form of the preparation may be in the form of a solution, suspension or emulsion in oil or aqueous medium, and may contain customary dispersing, suspending or stabilizing agents. Also, for example, it may be in the form of a dry powder that is used by dissolving it in sterile, pyrogen-free water before use.
  • the crystalline form of the compound of Formula 1 of the present invention may also be formulated in a suppository form using a conventional suppository base such as cocoa butter or other glycerides.
  • a solid dosage form for oral administration can be capsules, tablets, pills, powders and granules, and capsules and tablets are particularly useful. Tablets and pills are preferably prepared with an enteric coating.
  • a solid dosage form can be prepared by mixing the crystalline form of the compound of formula 1 of the present invention with one or more inert diluents such as sucrose, lactose, starch, and the like, and a carrier such as a lubricant, disintegrant, binder, etc., such as magnesium stearate.
  • it may be formulated in a transdermal dosage form, for example, a lotion, ointment, gel, cream, patch or spray, and the like.
  • the pharmaceutical composition according to the present invention is suitable for preventing or treating sphingosine-1-phosphate receptor-related diseases.
  • the pharmaceutical composition may be used for the treatment of autoimmune disorders including multiple sclerosis.
  • the pharmaceutical composition can be used for the prevention or treatment of diseases caused by undesirable lymphocyte infiltration involving sphingosine-1-phosphate.
  • the pharmaceutical composition can be used for the prevention or treatment of immunomodulatory disorders.
  • the immunomodulatory abnormality is, for example, systemic lupus erythematosus, chronic rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis autoimmune selected from the group consisting of sclerosis, amyotrophic lateral sclerosis (ALS), arteriosclerosis, atherosclerosis, scleroderma and autoimmune hepatitis; It may be a chronic inflammatory disease, but is not limited thereto.
  • prevention refers to reducing or eliminating the possibility of contracting a disease.
  • treatment means stopping, delaying, or alleviating the progression of a disease when used for an object showing symptoms of onset.
  • Form C, Form F, Form II and/or Form V of din-4-carboxylic acid or a pharmaceutically acceptable salt thereof has pharmacological activity as a sphingosine-1-phosphate receptor agonist and at the same time stability, e.g. It has excellent pharmaceutical properties such as thermal stability and storage stability.
  • thermogravimetric analysis TGA
  • DSC differential scanning calorimetry
  • crystalline form A A crystalline form (hereinafter referred to as "crystalline form A") of compound 1 having an X-ray powder diffraction (XRPD) pattern of 1 (156 g, two step yield 69.0%) was obtained.
  • XRPD X-ray powder diffraction
  • Form A was dissolved in dimethylformamide at 60° C. to make a solution, and then filtered with a cold acetonitrile solvent through a 0.2 ⁇ m nylon filter.
  • dimethylformamide and acetonitrile were used in a ratio of 1:10. After filtration with acetonitrile, a solid was not formed and the solution was maintained, and when stirred at room temperature for 1 day, a white solid was produced and changed into a suspension.
  • XRPD analysis was performed using a Panalytical Xpert Pro MPD diffractometer using an incident beam of Cu radiation. After compacting a sample of about 20 to 30 mg so that it has a flat surface on the glass sample holder, set the generator to 45 kV (acceleration voltage), 40 mA (filament emission), and then set it to reflection mode (not-spin). measured. Bragg angles (2 ⁇ ) in the range of 4 to 40° were measured with a step size of 0.026° and a Time per step condition of 51 seconds. XRPD patterns were classified and processed using HighScore Plus 2.2c software and the results are shown in Figure 1 and Table 2.
  • TGA/DSC combo analysis was performed using a Mettler-Toledo TGA/DSC3+ analyzer. The sample was placed in an open aluminum pan, the pan was sealed, the lid pierced, and then inserted into the TG furnace. Heated under nitrogen at a rate of 10° C./min from 30° C. up to 250° C. The results are shown in FIG. 2 .
  • Form F was prepared by the following two methods.
  • XRPD analysis was performed using a Panalytical Xpert Pro MPD diffractometer using an incident beam of Cu radiation. After compacting a sample of about 20 to 30 mg to have a flat surface on a glass sample holder, the generator was set to 45kV (acceleration voltage), 40mA (filament emission), and then measured in reflection mode (not-spin). . Bragg angles (2 ⁇ ) in the range of 4 to 40° were measured with a step size of 0.026° and a Time per step condition of 51 seconds. XRPD patterns were classified and processed using HighScore Plus 2.2c software and the results are shown in Figure 4 and Table 3.
  • TGA/DSC combo analysis was performed using a Mettler-Toledo TGA/DSC3+ analyzer. The sample was placed in an open aluminum pan, the pan was sealed, the lid pierced, and then inserted into the TG furnace. Heated under nitrogen at a rate of 10° C./min from 30° C. up to 250° C. The results are shown in FIG. 5 .
  • DSC results show a broad endothermic peak at about 86 °C (peak), which corresponds to the initial weight loss observed in TGA, which was expected due to desolvation. Upon further heating, an endothermic peak is observed at about 222° C. (onset), which may be due to the melting of Form A. Based on DSC, Form F can be converted to Form A upon heating/desolvation.
  • Form II was prepared by the following two methods.
  • Form A was dissolved in dimethyl sulfoxide to prepare a solution, and then slowly added isopropyl alcohol.
  • dimethyl sulfoxide and isopropyl alcohol were used in a ratio of 1:20. After stirring at room temperature for 1 day, it was refrigerated for 3 days. If a precipitate formed, it was filtered through a 0.45 ⁇ m PVDF filter.
  • XRPD analysis was performed using a Panalytical Xpert Pro diffractometer equipped with a Cu X-ray tube and a Pixcel detector system. After compacting a sample of about 20 to 30 mg to have a flat surface on a glass sample holder, the generator was set to 45kV (acceleration voltage), 40mA (filament emission), and then measured in reflection mode (not-spin). . Bragg angles (2 ⁇ ) in the range of 4 to 40° were measured with a step size of 0.026° and a Time per step condition of 51 seconds. XRPD patterns were classified and processed using HighScore Plus 2.2c software and the results are shown in Figure 6 and Table 4.
  • DSC was measured using a Mettler Toledo DSC1 system. A sample of about 2-5 mg was weighed and placed in 40 ⁇ L Al crucible (flat-bottomed aluminum pan with one pin-hole lid) to make one pin hole. Thereafter, the sample was heated from 25° C. to 350° C. at a rate of 10° C./min to measure DSC. During the measurement, nitrogen gas was supplied to the inside of the instrument at a rate of 70 mL/min to prevent the inflow of oxygen and other gases. Data collection and evaluation were performed using the software STARe (FIG. 7).
  • the TGA was measured using a Mettler Toledo TGA/DSC 1 module. Approximately 4-8 mg of the sample was weighed and placed in 100 ⁇ L Al crucible (flat-bottomed aluminum crucibles). Thereafter, the TGA was measured by heating the sample from 30°C to 350°C at a rate of 10°C/min. During the measurement, nitrogen gas was supplied to the inside of the instrument at a rate of 80 mL/min to prevent the inflow of oxygen and other gases. Data collection and evaluation were performed using the software STARe (FIG. 7).
  • Form A was dissolved in a mixed solvent of tetrahydrofuran and water 5:1 to prepare a solution, and then o-xylene was slowly added. At this time, tetrahydrofuran/water mixed solvent and o-xylene were used in a ratio of 1:20. After stirring at room temperature for 1 day, it was refrigerated for 3 days. If a precipitate formed, it was filtered through a 0.45 ⁇ m PVDF filter.
  • XRPD analysis was performed using a Panalytical Xpert Pro diffractometer equipped with a Cu X-ray tube and a Pixcel detector system. After compacting a sample of about 20 to 30 mg to have a flat surface on a glass sample holder, the generator was set to 45kV (acceleration voltage), 40mA (filament emission), and then measured in reflection mode (not-spin). . Bragg angles (2 ⁇ ) in the range of 4 to 40° were measured with a step size of 0.026° and a Time per step condition of 51 seconds. XRPD patterns were classified and processed using HighScore Plus 2.2c software and the results are shown in Figure 8 and Table 5.
  • DSC was measured using a Mettler Toledo DSC1 system. A sample of about 2-5 mg was weighed and placed in 40 ⁇ L Al crucible (flat-bottomed aluminum pan with one pin-hole lid) to make one pin hole. Thereafter, the sample was heated from 25° C. to 350° C. at a rate of 10° C./min to measure DSC. During the measurement, nitrogen gas was supplied to the inside of the instrument at a rate of 70 mL/min to prevent the inflow of oxygen and other gases. Data collection and evaluation were performed using the software STARe (FIG. 7).
  • the TGA was measured using a Mettler Toledo TGA/DSC 1 module. Approximately 4-8 mg of the sample was weighed and placed in 100 ⁇ L Al crucible (flat-bottomed aluminum crucibles). Thereafter, the TGA was measured by heating the sample from 30°C to 350°C at a rate of 10°C/min. During the measurement, nitrogen gas was supplied to the inside of the instrument at a rate of 80 mL/min to prevent the inflow of oxygen and other gases. Data collection and evaluation were performed using the software STARe (FIG. 7).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate et, plus spécifiquement, l'acide 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazole-5-ylméthoxy)-3,4-dihydro-naphthalène-2-ylméthyl]-pipéridine-4-carboxylique de formule chimique 1, ou une forme cristalline d'un solvate ou d'un sel pharmaceutiquement acceptable de celui-ci.
PCT/KR2022/005375 2021-04-14 2022-04-13 Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate WO2022220598A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280026332.XA CN117120425A (zh) 2021-04-14 2022-04-13 鞘氨醇-1-磷酸酯受体激动剂的晶体形式

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0048826 2021-04-14
KR20210048826 2021-04-14

Publications (1)

Publication Number Publication Date
WO2022220598A1 true WO2022220598A1 (fr) 2022-10-20

Family

ID=83640813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/005375 WO2022220598A1 (fr) 2021-04-14 2022-04-13 Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate

Country Status (3)

Country Link
KR (1) KR20220142381A (fr)
CN (1) CN117120425A (fr)
WO (1) WO2022220598A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1826197A1 (fr) * 2004-12-13 2007-08-29 Ono Pharmaceutical Co., Ltd. Dérivé d'acide aminocarboxylique et applications thérapeutiques dudit dérivé
WO2008064320A2 (fr) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Analogues d'hydrindane ayant une activité agoniste de récepteur de sphingosine-1-phosphate
US20080200535A1 (en) * 2006-08-25 2008-08-21 Asahi Kasei Pharma Corporation Amine Compounds
KR20140104376A (ko) * 2013-02-20 2014-08-28 주식회사 엘지생명과학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물
US10166250B2 (en) * 2009-08-05 2019-01-01 Biogen Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1826197A1 (fr) * 2004-12-13 2007-08-29 Ono Pharmaceutical Co., Ltd. Dérivé d'acide aminocarboxylique et applications thérapeutiques dudit dérivé
US20080200535A1 (en) * 2006-08-25 2008-08-21 Asahi Kasei Pharma Corporation Amine Compounds
WO2008064320A2 (fr) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Analogues d'hydrindane ayant une activité agoniste de récepteur de sphingosine-1-phosphate
US10166250B2 (en) * 2009-08-05 2019-01-01 Biogen Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
KR20140104376A (ko) * 2013-02-20 2014-08-28 주식회사 엘지생명과학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물

Also Published As

Publication number Publication date
CN117120425A (zh) 2023-11-24
KR20220142381A (ko) 2022-10-21

Similar Documents

Publication Publication Date Title
US7135485B2 (en) Pioglitazone hydrochloride
WO2020040467A1 (fr) Polymorphe cristallin de chlorhydrate de 8-bromo-2-(1-méthylpipéridin-4-ylamino)-4-(4-phénoxyphénylamino)pyrido[4,3-d]pyrimidin-5(6h)-one et procédé de préparation associé
WO2021137369A1 (fr) Nouveau co-cristal d'empagliflozine
WO2016117814A2 (fr) Nouvelle forme cristalline d'un dérivé de benzimidazole et son procédé de préparation
WO2022220598A1 (fr) Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate
WO2017047970A1 (fr) Forme cristalline de linagliptine et procédé de préparation de cette dernière
WO2010110622A2 (fr) Nouvelles formes cristallisées de l'adéfovir dipivoxil et leurs procédés de préparation
WO2017116193A1 (fr) Formes cristallines d'un composé de thiénopyrimidine
WO2022220597A1 (fr) Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate
WO2014003400A1 (fr) Cocristal d'aripiprazole-acide organique, préparation ou composition le contenant et son procédé de préparation
WO2012008711A2 (fr) Dichloroacétate d'erlotinib et agent anticancéreux comprenant ce dernier
WO2022220599A1 (fr) Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate
WO2022220600A1 (fr) Forme cristalline d'un agoniste du récepteur de la sphingosine-1-phosphate
JP2000508299A (ja) 抗ウイルス作用を有する置換キノリン誘導体
CA1273335A (fr) Derives pyrrolo ¬1,2-a| ¬4,1| benzoxazepine
WO2022220601A1 (fr) Sel pharmaceutiquement acceptable d'agoniste du récepteur de la sphingosine-1-phosphate, et forme cristalline de celui-ci
WO2024072108A1 (fr) Nouvelle forme cristalline d'énavogliflozine et son procédé de préparation
WO2010062147A2 (fr) Forme cristalline d'adefovir fipivoxil, procédé de préparation associé et composition pharmaceutique contenant cette forme
WO2024072109A1 (fr) Nouveau co-cristal d'énavogliflozine
WO2022065895A1 (fr) Nouveau sel d'un dérivé d'empagliflozine, en tant qu'inhibiteur de sglt-2, et hydrate de sel
WO2020111524A1 (fr) Sel et forme cristalline d'un composé de puropyrimidine et utilisation pharmaceutique associée
WO2023014160A1 (fr) Forme cristalline de phénylcarbamate et son procédé de préparation
WO2024090917A1 (fr) Nouveau sel de dérivé de diméthyl-2,3-dihydro-1h-indène et ses procédés de préparation
US20040097528A1 (en) Crystalline solid famciclovir forms I, II, III and preparation thereof
WO2017091041A1 (fr) Nouveau sel de fimasartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22788453

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22788453

Country of ref document: EP

Kind code of ref document: A1